Group items tagged

With more than fifty thousand members and certified professionals from ninety countries around the globe, the American College of Sports Medicine represents seventy occupations within the field of sports medicine. From academicians to students and from personal trainers to physicians, ACSM is dedicated to helping people worldwide live longer, healthier lives. To advance this mission, the association established the Research Grant Program through the ACSM Foundation, its charitable arm, in 1989. Through the program, grants of up to $10,000 will be awarded to support basic and applied research in exercise science. Funding is primarily targeted to new or junior investigators within seven years of attaining a terminal degree (e.g., PhD, EdD) and is expected to provide seed money support after which further funding would be sought from other sources. Grants are open to all ACSM members in good standing. See the American College of Sports Medicine website for complete program guidelines and application instructions.

The Foundation for the History of Women in Medicine will provide one $5000 grant to support travel, lodging, and incidental expenses for a flexible research period between July 1st 2014 - June 30th 2015. Foundation Fellowships are offered for research related to the history of women to be conducted at the Center for the History of Medicine at the Francis A. Countway Library of Medicine. Preference will be given to projects that deal specifically with women physicians or other health workers or medical scientists, but proposals dealing with the history of women's health issues may also be considered.

The Society for the History of Navy Medicine requests paper proposals on any topic related to the history of medicine in the maritime environment for its panel(s) hosted by the Naval Academy McMullen Naval History Symposium, 19 - 20 September 2019. A 250 word precis (as a Word document) and brief personal bio should be submitted to the Society Executive Director no later than 15 February 2019. Generous travel grants are available for graduate / professional students whose papers are selected for presentation.

This Funding Opportunity Announcement (FOA) encourages research grant applications from investigators who propose to study research topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Research focused on improving blood donor health, the safety and availability of blood products, and improving the practice of transfusion medicine is critical to public health. Research designed to better understand the determinants of transfusion-associated adverse events and how best to minimize transfusion risks is also important. Research is also needed to maintain an adequate blood supply by minimizing the risks associated with the donation process and developing enhanced recruitment and retention programs.

This Funding Opportunity Announcement (FOA) encourages research grant applications from investigators who propose to study research topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Research focused on improving blood donor health, the safety and availability of blood products, and improving the practice of transfusion medicine is critical to public health. Research designed to better understand the determinants of transfusion-associated adverse events and how best to minimize transfusion risks is also important. Research is also needed to maintain an adequate blood supply by minimizing the risks associated with the donation process and developing enhanced recruitment and retention programs.

Purpose This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors, associated core technologies and integrated approaches that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

The International Congress for the History of Pharmacy is a biennial meeting of historians, pharmacists and other researchers and health professionals from around the world interested in the history of pharmacy and pharmaceuticals. This year's Congress is co-sponsored by AIHP and the International Society for the History of Pharmacy, and is supported by a generous grant from the United States Pharmacopeial Convention (USP). The conference will be held in Washington, DC, at the Capital Hilton, on September 5-8, 2019. The theme of the Congress is "The Pharmacist and Quality Medicines." Four plenary lectures and more than 50 papers will focus on a broad range of topics related to all aspects of history of pharmacy and medicines, including the training and regulation of pharmacists and the social, scientific, technologic, and economic aspects of pharmaceuticals and the pharmaceutical industry. The conference will be of interest to scholars in the history of pharmacy and medicine and related fields. Plenary lectures will be given by noted historians William B. McAllister, Jacalyn Duffin, Michael Flannery, and Lucas Richert. The full conference schedule is available here. The conference website can be found here.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS Resource-based Centers Program (P30) for research areas within its mission in musculoskeletal biology and medicine. The Resource-based Centers will provide critical research infrastructure, shared facilities, services, and/or resources to groups of investigators conducting research on musculoskeletal biology and medicine, enabling them to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively, with the broad overall goal of accelerating, enriching, and enhancing the effectiveness of ongoing basic, translational, and clinical research and promoting new research within the NIAMS mission.

This Funding Opportunity Announcement (FOA) invites an application from the current awardee institution of the Accelerating Medicines Partnership in Type 2 Diabetes Knowledge Portal (AMP T2D KP). The AMP T2D program is a collaborative partnership between the NIH, pharmaceutical companies, and nonprofit organizations to develop new models for identifying and validating promising biological targets to serve as biomarkers and/or for drug discovery (www.nih.gov/research-training/accelerating-medicines-partnership-amp/type-2-diabetes). This is a one-time FOA to provide funds to the AMP T2D KP to continue the development of the web portal and underlying, curated knowledge base; as well as to become the flagship resource encompassing the myriad types of data and information that provides an understanding of the biological heterogeneity in patients with T2D and its complications. In its next five-year period, the AMP T2D KP will be expected to expand the KPs data sets and traits, import additional data types, deploy additional analytical and visualization tools, and increase its utility to a more diverse user base. To support the conduct of these studies, the AMP T2D KP will coordinate, support, and work with companion Functional Genomic Project awardees (RFA-DK-19-012) to form a Consortium. The AMP T2D KP will also oversee an opportunity pool of funds to solicit collaborative projects to accomplish the objectives of the Consortium.

RGK Foundation awards grants in the broad areas of Education, Community, and Health/Medicine. The Foundation's primary interests within Education include programs that focus on formal K-12 education (particularly mathematics, science and reading), teacher development, literacy, and higher education. Within Community, the Foundation supports a broad range of human services, community improvement, abuse prevention, and youth development programs. Human service programs of particular interest to the Foundation include children and family services, early childhood development, and parenting education. The Foundation supports a variety of Community Improvement programs including those that enhance non-profit management and promote philanthropy and voluntarism. Youth development programs supported by the Foundation typically include after-school educational enrichment programs that supplement and enhance formal education systems to increase the chances for successful outcomes in school and life. The Foundation is also interested in programs that attract female and minority students into the fields of mathematics, science, and technology. The Foundation's current interests in the area of Health/Medicine include programs that promote the health and well-being of children, programs that promote access to health services, and Foundation-initiated programs focusing on ALS.

The National Library of Medicine (NLM) offers support for innovative research in biomedical informatics and data science. The scope of NLM's interest in the research domain of informatics is broad and interdisciplinary, developing methods and approaches in biomedical computing, data science and related information fields for application domains of health and biomedicine, including health care delivery, basic biomedical research, clinical and translational research, precision medicine, public health, biosurveillance, health information management in disasters, and similar areas. NLM defines biomedical informatics as the science of optimal representation, organization, management, integration and presentation of information relevant to human health and biology, for purposes of learning, sharing and use.

Dr. Ralph S. Paffenbarger, Jr., a co-recipient of the first Olympic Prize in Exercise Science and Sports Medicine, made an extraordinarily generous gift to the American College of Sports Medicine by donating his share of the award to the College's capital campaign with the monies added to the College's epidemiology endowment. The interest on this contribution makes this grant possible. The intent of this award is to encourage researchers early in their career to become involved with physical activity epidemiology. The applications may focus on observational studies of physical activity and health outcomes, or on randomized controlled trials that are clearly focused on physical activity and important public health issues.  Applicants are expected to apply within two (2) years of receiving a postgraduate degree or completion of clinical training. The award will be in the amount of $10,000 for a one year period.

The Society for Adolescent Health and Medicine Visiting Professorship in Adolescent Research was established in 1995 with the first award being given for 1995. The intent of this award was to provide an educational experience in Adolescent Research for a group of health care providers and researchers who might not otherwise have the opportunity to benefit from the professor's expertise

The intent of this award is to recognize individuals nationally and internationally for their commitment to improving the health of and health care resources for adolescents and young adults. The award honors individuals who have made a lifelong commitment to the health and well-being of adolescents, who have exhibited leadership in the field, made significant contributions to the advancement of the field, or has inspired others through their work, research, education or leadership. Membership in the Society for Adolescent Health and Medicine is not a requirement for eligibility to be considered for this award.

The Fiscal Year 2015 (FY15) Joint Program Committee 8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP) Extremity Regeneration Technology/Therapeutic Development Award (ERTTDA) is intended to support the translation of promising preclinical findings into products focused on extremity regeneration. The focus is on bone and soft tissue reconstruction, limb and tissue salvage technologies, and regenerative medicine technologies for the treatment of trauma-induced damage.

ADPKD affects ~500,000 patients in US and ~10 million world-wide with limited treatment options. ADPKD patients develop progressive cyst growth in kidney over decade, eventually leading to deterioration of kidney function combined with severe pain, hematuria and fibrosis/inflammation. Two mutations (Pkd1/pkd2) account for >95% of ADPKD cases, and the dominant nature and high penetration rate of this disease affects patient families in a profoundly negative way in both health care and social interactions. There is currently no FDA approved medicine for ADPKD in US, although vasopressin antagonist and somatostatin mimetics are in phase 3 studies. GSK aims to deliver innovative medicine to treat ADPKD based on novel mechanism of action. We are particularly interested in agents or targets that function upstream of final cellular proliferative response and have solid genetic/pharmacological evidence supporting the role of such target/agents in human ADPKD. We are also interested in mechanisms/targets that can treat both liver and kidney cyst progression. We are open to form a partnership or alliance with perspective investigators/sponsors to pursue such new target/agents upon review and approval.

The Grenvik Family Award for Ethics Award honors a Society of Critical Care Medicine member who has promoted the ethical and humane delivery of critical care. The award was established in memory of Dr. Christer Grenvik, who died very early in his medical career. During his last two years of life, Christer Grenvik became deeply religious and concerned with the critically and terminally ill patient's autonomy when deciding on choice of treatment. He became particularly interested in the ethical problems in these situations and compassionate care of patients in the terminal stage. The Grenvik Family Award for Ethics Award memorializes Christer Grenvik's great concern for these issues. The recipient receives $1,000 and complimentary registration to attend the Critical Care Congress. Candidates are nominated for the award by an SCCM member or members of the award subcommittee. To be eligible, nominees must have made a significant contribution to addressing an ethical problem in critical care; be an SCCM member in good standing; and have demonstrated commitment to SCCM through involvement in SCCM committees or other SCCM activities at the local, regional, national, or international level.

This Funding Opportunity Announcement (FOA) is a phased innovation initiative to facilitate multi-omics/integrative approaches to identify omics profiles associated with protection against multiple aging conditions, with exceptional health span, and to refine strategies for utilizing these profiles for therapeutics development. Specifically, a phased innovation cooperative agreement mechanism (UH2/UH3) involving an interdisciplinary research team will be used to support a single project that will conduct integrative analysis of person -specific multiple omics measurements (e.g., transcriptomics, proteomics, metabolomics) generated across multiple tissues ; the multi-omic profiling should be conducted on individuals from extensively phenotyped cohorts with substantial numbers of long-lived individuals with characteristics of exceptionally healthy aging and appropriate controls. It will also: 1) harmonize and extend the use of existing phenotypic data from these studies to apply phenomics to transcriptomic, proteomic, metabolomic findings, 2) select animal model species or strains with varying life spans for comparative omics studies and identify potential determinants of species differences in longevity and rates of disease development, 3) develop appropriate computational and analytical tools to identify omics profiles associated with exceptional longevity and healthy aging, 4) apply translational bioinformatics approaches and leverage existing publicly available drug signatures databases to identify molecules that could produce profiles associated with exceptionally healthy aging and 5) exchange data with other NIH/NIA-supported related omics activities and other public-private partnerships (e.g., Trans-Omics for Precision Medicine (TOPMed), Accelerating Medicines Partnership- Alzheimers Disease (AMP-AD) for data harmonization and analysis.

Supported by the NIH Common Fund (Common Fund) Science of Behavior Change (SOBC) Program, this Funding Opportunity Announcement (FOA) solicits exploratory and developmental research project applications (R21) that will further the goal of the SOBC Program to advance a mechanisms-focused, experimental medicine approach to behavior change research. Funded projects in the SOBC Research Network have developed experimental manipulations, assays, and/or measures (hereafter referred to as assays for brevity) to support an experimental medicine approach to behavior change research. The SOBC Measures Repository assays are accessible from the SOBC Research Network Open Science Framework (OSF) page at https://osf.io/zp7b4. The goal of this announcement is to leverage SOBC Measures Repository assays of putative targets in self-regulation, stress reactivity and stress resilience, and interpersonal and social processes domains to (1) engage a selected putative target(s)/mechanism(s) of action or verify target engagement of the selected target(s)/mechanism(s) of action, and (2) test the degree to which engaging the putative target(s)/mechanism(s) of action produces a short-term desired change in a health behavior. Putative targets are the mechanisms or processes hypothesized to be malleable and play a causal role in producing behavior change, including medical regimen adherence.

Supported by the NIH Common Fund (Common Fund) Science of Behavior Change (SOBC) Program, this Funding Opportunity Announcement (FOA) solicits competitive revision (formerly known as a competitive supplement) applications to NIH-supported clinical trials awarded as research project R34 grants. The goal of the SOBC Program is to advance a mechanisms-focused, experimental medicine approach to behavior change research. Funded projects in the SOBC Research Network (https://commonfund.nih.gov/behaviorchange/fundedresearch) have developed experimental manipulations, assays, and/or measures (hereafter referred to as assays for brevity) to support an experimental medicine approach to behavior change research. The SOBC Measures Repository is accessible from the SOBC Research Network Open Science Framework (OSF) page at https://osf.io/zp7b4. The goal of this FOA is to accelerate the adaptation, validation, and translation of SOBC Research Network assays for use in ongoing clinical trials. This FOA calls for the integration of SOBC Research Network assays into active NIH-supported clinical trials of drugs, devices, procedures, or behavior modifications. As such, the active NIH-supported clinical trial used to respond to this FOA does not have to be a behavior change trial or identify behavior change as a primary outcome. The integration of SOBC Research Network assays into ongoing clinical trials will accelerate the development of interventions and experimental manipulations that have been shown to engage specific mechanisms of behavior change and the development of assays that verify engagement of those behavior change targets.